NONMEM Users Network Archive

Hosted by Cognigen

[NMusers] PhD Studentship - Model-based precision dosing of levofloxacin in critically ill patients, University of Manchester

From: Kayode Ogungbenro <>
Date: Fri, 9 Nov 2018 13:27:01 +0000

(MRC DTP) Model-based precision dosing of levofloxacin in critically ill pa=
University of Manchester | Faculty of Biology, Medicine and Health | Manche=
ster | United Kingdom

Dr A Darwich, Dr K Ogungbenro, Dr T Felton
Application Deadline Friday, November 16, 2018

Project Description
Community-acquired pneumonia (CAP) is a leading cause of morbidity and mort=
ality in adults and children worldwide1. In the UK, CAP accounts for over 1=
00,000 hospital admissions annually. Levofloxacin is a broad spectrum antib=
iotic licenced for the treatment of CAP. Resistance of levofloxacin is incr=
easingly identified in patients with CAP. The current, fixed dose of levofl=
oxacin was established in early phase trials of healthy volunteers and non-=
critically ill patients. Antibiotic pharmacokinetics has been demonstrated =
to be different in critically ill patients compared to healthy volunteers w=
ith marked between subject variability. Between-subject variability results=
 in under-dosing and treatment failure in a significant proportion of patie=
nts. The optimal dose of levofloxacin in critically ill patients with CAP i=
s still not clearly defined.

The objective of this project is to develop a model-based precision dosing =
algorithm for levofloxacin in critically ill patients to improve treatment =
outcome, using mechanistic model that account for between-subject variabili=
ty in the pharmacokinetics.

Kayode Ogungbenro, PhD
Lecturer in Cancer Pharmacometrics | Division of Pharmacy and Optometry | =
School of Health Sciences
The University of Manchester | Manchester M13 9PT | United Kingdom
Tel : + 44(0)161 275 2399
Fax: +44(0)161 275 8349

Received on Fri Nov 09 2018 - 08:27:01 EST

The NONMEM Users Network is maintained by ICON plc. Requests to subscribe to the network should be sent to: Once subscribed, you may contribute to the discussion by emailing: